PULMONARY SURFACTANT is a lipoprotein complex of phospholipids and at least four different associated proteins, labeled surfactant proteins (SP) A, B, C, and D. The main function of surfactant is to lower the surface tension at the air-liquid interface and stabilize alveoli at low lung volumes (34) . This property decreases the work of breathing and prevents extravasation of fluid into the alveolar space. The hydrophobic surfactant proteins, SP-B and SP-C, have an essential role in surfactant adsorption to the air-liquid interface (13, 26) . In the presence of SP-B, the hydrophilic SP-A and SP-D enhance the surface activity and protect surfactant from inactivation by plasma proteins (4, 14) . SP-A knockout mice studies confirm the role of SP-A in enhancement of the surface activity of surfactant, at low lipid concentrations, and its participation in the host-defense properties of the lung (20, 21) .
Surfactant deficiency has been established as the primary cause for respiratory distress syndrome (RDS) in premature infants, and replacement therapy has reduced mortality and decreased the severity of illness of RDS in preterm infants (5, 23) . Surfactant preparations used for replacement therapy can be divided into two general groups. First, natural surfactant extracts [Curosurf, Survanta, and Infrasurf, also known as calf lung surfactant extract (CLSE)] obtained by methanolchloroform extraction of natural lung surfactant or minced lung. These preparations consist mainly of lipids (99% by weight) and SP-B and SP-C (1% by weight). Second, synthetic surfactants (Exosurf) consist mainly of dipalmitoyl phosphatidylcholine with small amounts of alcohol and tyloxapol added to enhance its adsorption to the air-water interface. Exosurf does not contain any of the surfactant proteins.
Although surfactant replacement therapy has improved the clinical course of RDS, the incidence of chronic lung disease of prematurity (bronchopulmonary dysplasia; BPD) in surfactant-treated preterm infants has not significantly changed (23) . BPD is characterized by marked inflammation and oxidantmediated lung injury generated by reactive oxygen species. These species produce lung damage by initiation of lipid peroxidation of biological membranes and oxidation of critical cellular proteins and nucleic acids. Antioxidant enzymes, such as superoxide dismutase (SOD) and catalase, limit oxidant-mediated injury by their ability to scavenge reactive oxygen species (2, 31, 33) . It has therefore been argued that coadministration of antioxidants during surfactant treatment for RDS may decrease the incidence of BPD. For example, SOD-surfactant liposomes mitigated hyperoxic lung injury in premature rabbits (32) , and phase I and II clinical trials of recombinant human SOD (rhCuZn-SOD) administered intratracheally to premature infants have been performed (27) .
Several proteins have been shown to inhibit the surface activity of surfactant in vivo and in vitro. Different serum proteins added to control surfactant revealed marked rank order of potency in interfering with surfactant function (1, 28) . The strongest inhibition was exerted by fibrinogen followed by human serum, the weakest inhibitor being albumin. Furthermore, Seeger et al. (29, 30) noted that various surfactant preparations differ in their sensitivity to specific inhibitory plasma proteins. We therefore hypothesized that CuZn-SOD, a negatively charged low-molecularweight protein (32,600 mol wt), coadministered with surfactant may interfere with its ability to lower surface tension at the air-liquid interface, especially when various components of surfactant have been damaged by reactive oxygen and nitrogen species. Thus we performed a number of biophysical studies to quantify the inhibitory effects of bovine CuZn-SOD on in vitro surface activity of two different surfactant preparations: CLSE and Exosurf. In a second series of experiments, we repeated these measurements after exposure of these surfactant preparations to peroxynitrite (ONOO Ϫ ), a strong oxidizing and nitrating agent, and determined synergistic effects of serum protein inactivation and the protective effects of SP-A.
MATERIALS AND METHODS
Chemicals. Normal human serum was obtained by pooling from several healthy volunteers, and its protein concentration was determined by the bicinchoninic acid (BCA) method. Bovine CuZn-SOD was obtained from DDI Pharmaceuticals (Mountain View, CA). Bovine serum albumin (BSA) and all other chemicals unless specified were from Sigma Chemical (St. Louis, MO).
Surfactants preparations. CLSE (Infrasurf) was a generous gift of ONY (Buffalo, NY). The organic solvent was removed by vacuum distillation and nitrogen evaporation, and the dried CLSE was resuspended in 0.15 M NaCl by mechanical vortexing. Exosurf was provided by Glaxo-Wellcome (Research Triangle Park, NC).
SP-A was purified from bronchoalveolar lavage of patients with alveolar proteinosis as previously described (10, 11) . SP-A was dissolved in 10 mM 10 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES; pH 7.4), and protein concentration was determined by the BCA method and stored in small aliquots at Ϫ20°C until use.
Surface tension measurements. Stock solutions of CLSE and Exosurf were diluted to the desired lipid concentrations [0.1-3 mg phospholipid (PL)/ml] in a 10 mM HEPES buffer (150 mM NaCl, 2 mM CaCl 2 , 5 mM KCl, and 1.2 mM MgCl 2 ; pH 7.4). The surfactant suspension was incubated with the indicated concentration of CuZn-SOD, BSA, SP-A, and serum (see below) for 15 min at 37°C. The surface tension of the surfactant mixtures was measured during dynamic compression using a pulsating bubble surfactometer (PBS, Electronetics, Amherst, NY), as described in detail by Enhorning et al. (8) . Briefly, this apparatus allows the continuous determination of the pressure drop across the interface of a small air bubble formed in a surfactant-containing subphase. The bubble was pulsed at a rate of 20 cycles/min between maximal and minimal radii of 0.55 and 0.4 mm (surface compression of 50%). Surface pressure and bubble radius were recorded every 100 ms, and surface tension was calculated from the law of Young and Laplace for a sphere. Oscillation of the bubble continued for 10 min or until the surface tension at minimal radius (T min ) was Ͻ3 mN/m.
Exposure of surfactant to ONOO Ϫ . ONOO Ϫ was synthesized in a quenched-flow reactor (25) . Solutions of 0.6 M sodium nitrite and 0.6 M HCl-0.7 M hydrogen peroxide were pumped at 10 ml/s into a T junction and mixed in a 3-mmdiameter 10-cm glass tube. The acid-catalyzed reaction of nitrous acid with hydrogen peroxide to form peroxynitrous acid was quenched by pumping 1.5 M sodium hydroxide at the same rate into a second T junction at the end of the glass tubing. The solution was treated with manganese dioxide to remove contaminated hydrogen peroxide and frozen at Ϫ20°C for as long as 1 wk. The top yellow layer, formed due to freeze fractionation, contained ϳ170-220 mM ONOO Ϫ as determined by absorbance at 302 nm in 1 M NaOH (⑀ 302 ϭ 1,670 M Ϫ1 ·cm Ϫ1 ).
Our previous studies indicate that exposure of CLSE to ONOO Ϫ plus 100 µM Fe 3ϩ -EDTA inhibits its ability to achieve low T min on dynamic compression (12) . In this study, we exposed CLSE or Exosurf (1 mg PL/ml) to ONOO Ϫ (0.5-1 mM) plus 100 µM Fe 3ϩ -EDTA for 15 min at 23°C and evaluated the effects of CuZn-SOD on modification of the ONOO Ϫ -mediated injury to surface activity of CLSE and Exosurf by using the PBS.
Statistical analysis. All results are expressed as means Ϯ SD. Statistical differences among group means at 0, 5, and 10 min of pulsation were determined by using one-way analysis of variance and the Bonferroni modification of the t-test.
RESULTS

Inhibition of surface activity by CuZn-SOD.
Samples of CLSE (1 mg PL/ml), suspended in HEPES buffer (pH 7.4) displayed a surface tension of 27 Ϯ 0.9 mN/m just before pulsation and a T min of Ͻ3 mN/m within 1 min of pulsation in a PBS. Addition of CuZn-SOD (5 or 10 mg/ml) impaired its adsorption to the interface, as indicated by the increased T min at time 0 min, and prevented the rapid drop to low T min with dynamic compression in a dose-dependent manner (Fig. 1) . The inhibitory effects of CuZn-SOD were ameliorated by increasing CLSE concentration to 3 mg PL/ml (data not shown). In contrast, BSA in concentrations up to 100 mg/ml did not inhibit the rapid drop of T min with pulsation, although T min just before pulsation was significantly higher than control (Fig. 1) . After pulsation in a PBS, the T min of Exosurf samples at low PL concentrations (0.1 mg/ml) decreased to Ͻ3 mN/m within 3 min. The presence of CuZn-SOD (1 or 2 mg/ml) delayed the drop of T min of Exosurf (Fig. 2) . At higher PL concentrations (Ͼ0.1 mg/ml), T min of Exosurf remained Ͼ28 mN/m, as previously reported (3, 9) .
Effects of BSA, serum, and SP-A on CuZn-SODmediated inhibition. The addition of CuZn-SOD (1-10 mg/ml) to CLSE (1 mg PL/ml) or Exosurf (0.1 mg PL/ml) samples in the presence of BSA (3-50% by weight) enhanced the inhibitory effect of BSA on T min during pulsation in a PBS, suggesting a synergistic detrimental effect of CuZn-SOD plus BSA on the surface activity of the surfactant mixtures (Figs. 3 and 4) . Normal human serum (2-5% by weight) significantly increased T min of CLSE (1 mg/ml) and Exosurf (0.1 mg/ml) at 0 min and prevented the drop of T min below 6 mN/m. The presence of CuZn-SOD (2 mg/ml) also potentiated the inhibitory effects of serum and prevented the drop of T min of CLSE below 10 mN/m even after 10 min of Fig. 1 . Effects of bovine CuZn-superoxide dismutase (SOD) on surface tension at minimal bubble radius (T min ) of calf lung surfactant extract (CLSE) as a function of time of pulsation in a pulsating bubble surfactometer (PBS). CuZn-SOD (5 or 10 mg/ml, n and l, respectively) or bovine serum albumin (BSA, 100 mg/ml, s) was incubated for 15 min at 37°C with CLSE [1 mg phospholipid (PL)/ml] suspended in 10 mM HEPES (pH 7.4). Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control CLSE (r). pulsation ( Figs. 5 and 6 ). On the other hand, addition of human SP-A (3% by weight) restored the ability of CLSE plus CuZn-SOD samples, but not Exosurf plus CuZn-SOD samples (not shown), to rapidly achieve low T min with dynamic compression (Fig. 3) .
Effects of SOD on ONOO Ϫ -injured CLSE. Exposure of CLSE (1 mg PL/ml) to 0.5 mM ONOO Ϫ plus 100 µM Fe 3ϩ -EDTA, capable of initiation and propagation of lipid peroxidation and oxidation and nitration of surfactant proteins (12) , significantly impaired the ability of CLSE to adsorb to the interface, as indicated by the increased T min immediately before the initiation of pulsations, and inhibited its ability to rapidly reach a low T min with dynamic compression. This oxidantmediated injury to CLSE was more severe in the presence of CuZn-SOD (5 mg/ml). SP-A (3% by weight) restored the ability of ONOO Ϫ -exposed CLSE to baseline (control) values (Fig. 7) . In contrast, exposure of Exosurf samples (0.1 mg PL/ml) to ONOO Ϫ (0.5-4 mM) plus 100 µM Fe 3ϩ -EDTA did not alter their surface properties (T min Ͻ3 mN/m within 3 min of pulsation).
This finding is consistent with the absence of unsaturated lipids and surfactant proteins in Exosurf.
DISCUSSION
Exogenous surfactant improves the lung distribution of intratracheally instilled substances and enhances their uptake into the alveolar epithelium (19, 24) . Jobe et al. (18) recently reported that the administration of recombinant adenoviral vectors used for gene therapy mixed with a surfactant preparation (Survanta), enhanced the efficiency of gene transfer into murine lungs. Similarly, Survanta delayed the clearance of instilled rhCuZn-SOD protein and prolonged its antioxidant activity measured at 48 h (6). This enhanced antioxidant activity in preterm animal and human lungs protects against oxidant stress and thus may prevent the development of BPD (7). However, before the widespread use of this approach, the effects of CuZn-SOD on the biophysical properties of surfactant need to be examined. Fig. 2 . Effects of bovine CuZn-SOD on T min of Exosurf. CuZn-SOD (1 or 2 mg/ml, n and l, respectively) was incubated with Exosurf (0.1 mg PL/ml) suspended in 10 mM HEPES (pH 7.4) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control Exosurf (s). Fig. 3 . Effects of BSA and surfactant protein A (SP-A) on bovine CuZn-SOD-mediated inhibition of surface activity of CLSE. BSA (r, 3% by weight) or SP-A (q, 3% by weight) was incubated with CLSE (1 mg PL/ml) in presence of CuZn-SOD (l, 10 mg/ml) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control CLSE (s). Fig. 4 . Effects of BSA on bovine CuZn-SOD-mediated inhibition of surface activity of Exosurf. BSA (50% by weight) was incubated with control Exosurf (0.1 mg PL/ml, n) or Exosurf in presence of CuZn-SOD (l, 1 mg/ml) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control Exosurf (r). Fig. 5 . Effects of CuZn-SOD on normal human serum-mediated inhibition of T min of CLSE. Samples of CLSE (1 mg PL/ml) were incubated with serum (5% by weight, n) or serum (5% by weight) in presence of CuZn-SOD (2 mg/ml, l) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ 1 SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control Exosurf (r).
Our data show that CuZn-SOD (0.5-10 mg/ml) adversely affected the ability of two distinct surfactant preparations at low PL concentrations to achieve a low T min with dynamic compression in a PBS. We used the smallest SOD concentration necessary to inhibit the T min of the surfactant under study. At first glance, surfactant and SOD concentrations used in these studies may seem outside the doses used clinically. However, it should be kept in mind that alveolar concentrations may differ dramatically from instilled ones because surfactant and SOD are cleared from the alveolar space at different rates. Matalon et al. (22) instilled two 125-mg (162 µmol) boluses of CLSE into the lungs of oxygen-treated rabbits 12 h apart (total instilled dose 324 µmol). Only 15% of the instilled dose (50 µmol) could be recovered in the bronchoalveolar lavage 12 h after the second instillation. Furthermore, it is not clear what fraction of this surfactant was released from the alveolar type II cells during the alveolar lavage. In preterm lambs with RDS, only ϳ13% of the exogenous surfactant dose can be recovered in the air spaces after 24 h of ventilation (17) . Also, since the distribution of instilled substances into air-filled lungs is heterogeneous, it is likely that some alveoli may contain very low concentrations of surfactant. Davis et al. (6) instilled rats with surfactant and 5 or 25 mg/kg of rhCuZn-SOD. Twenty-four hours later, the bronchoalveolar lavage rhSOD concentrations were 10 and 75 µg SOD/ml of lavage fluid. Because the lungs were lavaged with 7 ml of fluid, the total amounts of rhSOD in the epithelial lining fluid of these rats were 70 and 525 µg, respectively. By extrapolation from estimates for the human (ϳ1 ml), the adult rat lung would have an alveolar lining volume of 50 µl, and the concentrations of rhSOD at this time point would therefore be 1.4 and 10.5 mg/ml, respectively.
Proteins inhibit surfactant function by competing with the phospholipids for space at the air-liquid interface (15) . This is consistent with the observation that the albumin-mediated effect is abolished by an increase in surfactant concentration (16) . CuZn-SOD may also delay adsorption and increase T min of CLSE and Exosurf by interfering with the formation of a lipid monolayer at the air-liquid interface. However, the marked sensitivity to inhibition by CuZn-SOD compared with BSA suggests additional mechanisms may be responsible. One potential mechanism is a direct molecular interactions between CuZn-SOD and the lipid or protein components of the surfactant mixtures. For example, Seeger et al. (28) reported that fibrin monomers are very potent inhibitors of surfactant and suggested they formed a complex with one or more of the surfactant components. Differential sensitivity of the various surfactant to the inhibitory effects of serum proteins has been observed (29, 30) . Plausible reasons include differences in lipid composition, surfactant protein (SP-A, SP-B, SP-C) content, and presence of contaminating material during extraction. We were unable to directly compare the sensitivity of Exosurf and CLSE to inhibition by CuZn-SOD because we measured the T min of these two preparations at different PL concentrations. The T min of Exosurf at PL concentration of 1 mg/ml does not drop Ͻ28 mN/m with pulsation in a bubble surfactometer (50% area compression) (12) . However, we observed, as previously noted (3, 9) , that at lower PL concentration (0.1 mg/ml) low T min was achieved within few minutes of pulsation. It is important to note that this concentration of Exosurf may be lower than the clinically relevant range after exogenous replacement. On the other hand, the T min of CLSE (0.1 mg/ml) remained high during dynamic pulsation. Despite these limitations, two important differences between CLSE and Exosurf emerged. First, Exosurf was resistant to inactivation by ONOO Ϫ plus Fe 3ϩ -EDTA. This finding is consistent with the fact that Exosurf lacks oxidizable unsaturated lipids and surfactant proteins. Second, SP-A protected CLSE, but not Exosurf (data not shown), against inactivation by CuZn- Fig. 6 . Effects of CuZn-SOD on normal human serum-mediated inhibition of T min of Exosurf. Samples of Exosurf (0.1 mg PL/ml) were incubated with serum (2% by weight, q) or serum (2% by weight) in presence of CuZn-SOD (1 mg/ml, p) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control Exosurf (s). Fig. 7 . Effects of bovine CuZn-SOD on T min of peroxynitrite (ONOO Ϫ )-injured CLSE. CLSE (1 mg PL/ml) was exposed to ONOO Ϫ (0.5 mM) ϩ Fe 3ϩ -EDTA (100 µM) for 15 min at 23°C (s) followed by incubation with CuZn-SOD (0.5 mg/ml, l) or CuZn-SOD (0.5 mg/ml) in presence of SP-A (3% by weight; q) for 15 min at 37°C before T min measurement in a PBS. Values are means Ϯ SD (in some cases SD is less than width of symbols) for n Ն 3. * P Ͻ 0.05 from corresponding T min of control CLSE (not shown).
SOD, consistent with the knowledge that SP-A requires the presence of SP-B to enhance surface activity of surfactant (12, 15) .
Because bovine CuZn-SOD and rhCuZn-SOD are structurally and functionally very similar and the experiments were performed in vitro, the bovine source of CuZn-SOD was used in these studies. However, it should be noted this form of SOD may contain contaminants that may have contributed to the inhibition of surface activity.
The clinical use of CuZn-SOD may have important protective effects against oxidant-mediated tissue and surfactant injury. Therefore, despite our observation that at low phospholipid concentrations CuZn-SOD inhibited the surface activity of surfactant mixtures, the net effect may still be beneficial. Fortunately, this surfactant inactivation can be overcome either by increasing surfactant PL concentration or by adding SP-A to currently available hydrophobic protein-based surfactant preparations. Further in vivo studies are needed to determine the value and efficacy of each of these modifications.
